Myelodysplastic syndromes (MDS) are a group of clonal hematologic disorders found predominantly in the elderly. The molecular mechanisms underlying the development of MDS remain obscure. In order to begin to identify tumor suppressor genes involved in these disorders, we performed a detailed microsatellite allelotype of chromosomal deletions associated with MDS. DNAs from both bone marrow and peripheral blood of 32 MDS patients were studied using 84 highly informative microsatellite markers on all autosomal arms, excluding the short arms of the acrocentric chromosomes. A high percentage of loss of heterozygosity (LOH) was identified on chromosome 5q (40% of informative cases), 7q (45%), 17p (23%) and 20q (20%), which corresponds to the most common cytogenetic abnormalities reported in MDS. In addition, a high incidence of LOH (у20%) was observed on chromosomal arms which had not been previously reported including 1p (36%), 1q (35%), and 18q (23%). This extensive allelotype analysis focuses attention on several novel genomic regions that probably contain novel tumor suppressor genes whose loss of function contributes to the development of MDS. Leukemia (2000) 14, 805-810.
Introduction
Myelodysplastic syndrome (MDS) is recognized as a clonal disorder of multipotential stem cells showing qualitative and quantitative abnormalities of one or more cell lineages.
1,2 The French-American-British (FAB) co-operative group divided MDS into five types: refractory anemia (RA), refractory anemia with ring sideroblasts (RARS), refractory anemia with excess of blasts (RAEB), refractory anemia with excess of blasts in transformation (RAEB-t), and chronic myelomonocytic leukemia (CMML). 3 The molecular events involved in the development of this tumor are not well understood.
Malignant transformation and tumor progression results from a series of genetic changes. The alteration of tumor suppressor genes is among the most common molecular events that contribute to tumorigenesis. A variety of mechanisms exist for tumor suppressor gene inactivation. Loss of heterozygosity (LOH) in tumor cells has proven useful in mapping regions containing putative tumor suppressor genes. Many studies have shown that LOH at specific chromosomal sites is frequently associated with development of various cancers, eg 3p14-p23 in small cell lung carcinoma, 1p32-p36 in neuroblastoma, 13q14 in retinoblastoma, 1p36 in chronic myelocytic leukemia, and 11p13-p15 in Wilms' tumor.
sively, and the most frequent deletions are on chromosome Nos 5, 7 and 20. [6] [7] [8] Deletions on chromosome Nos 12, 13, and 17, although more rarely observed, are characteristic of MDS. 9 However, cytogenetic studies can not reveal small deletions such as allelic loss, which are below the resolution of cytogenetic analysis. LOH analysis is a powerful technique to identify structural alterations in the regions of tumor suppressor genes. 10 The paradigm is mutation of one allele and loss of the remaining allele, leading to homozygous inactivation of the gene. Focused studies of LOH in MDS have shown a high frequency of allelic alterations affecting 5q, 7q, and 17p. [11] [12] [13] However, a complete allelotype analysis of MDS has not yet been reported. To obtain a comprehensive view of the role of genetic alterations in the development of MDS, we performed an allelotype analysis of 32 cases utilizing 84 highly informative microstallite markers mapped to each of the autosomal arms, excluding the short arms of acrocentric chromosomes. We identified several new regions of frequent LOH on chromosomes 1p, 1q, and 18q. These studies form the framework to clone the tumor suppressor genes in these regions that are implicated in MDS.
Materials and methods

Clinical samples
Thirty-two paired samples of bone marrow and peripheral blood were obtained after informed consent from patients who were diagnosed between October 1996 and February 1998 from The Berlin-Frankfurt-Munster Group in Germany, Kyoto University School of Medicine, Japan, and Cedars-Sinai Medical Center, UCLA School of Medicine. The patients with MDS were classified according to the FAB criteria: 19 (60%) RA, 3 (9%) RARS, 5 (16%) RAEB, 3 (9%) RAEB-t, and 2 (6%) CMML.
Mononuclear cell isolation and DNA extraction
Mononuclear cells were isolated from bone marrow and peripheral blood by Ficoll-Hypaque density gradient centrifugation (Sigma Chemical, St Louis, MO, USA). The cells were washed twice with phosphate-buffered saline (PBS). Mononuclear cells from the peripheral blood contained у80% lymphocytes as measured by antibodies to CD4, CD8, and CD20 using flow cytometry (data not shown). Furthermore, fewer than 5% blast cells were detected in the peripheral blood of each of the patients at the time that the samples were obtained. Previous studies have shown that B and T lymphocytes are rarely part of the MDS clone.
1,2 Furthermore, greater than 80% of the bone marrow mononuclear cells in each sample were myeloid and erythroid nucleated cells. The abnormal MDS clone is usually predominant at diagnosis and is composed of the myeloid, erythroid and megakaryocytic cells. 1, 2 Thus, the DNA extracted from the peripheral blood mono-Leukemia nuclear cells predominantly represents the cells of the normal clone and the DNA extracted from the bone marrow mononuclear cells predominantly represents cells of the MDS clone.
DNA was extracted by conventional cell lysis and proteinase K (Sigma, St Louis, MO, USA) digestion in 100 mmol NaCl, 10 mmol Tris-HCl (pH 7.0), 25 mmol EDTA, and 0.5% sodium dodecyl sulfate (SDS) at 50°C overnight. DNA was purified by a phenol-chloroform extraction and precipitated with 3 mol sodium acetate and ethanol. The concentration and quality of DNA was measured by spectrophotometry by analysis of absorption at 260 and 280 nm wavelength.
Loss of heterozygosity analysis
The LOH analysis was performed by PCR amplification of microsatellite sequences. Primers for microsatellite sequences were obtained from Research Genetics (Huntsville, AL, USA) and are listed in Table 1 . Each PCR reaction contained 25 ng of DNA, 10 pmol of each of the primers, 2 nmol of each of . After amplification, PCR products were diluted five-fold in loading buffer containing 20 mM EDTA, 96% formamide, and 0.05% of both bromophenol blue and xylene cyanol. The samples were heated to 95°C for 5 min. Two l of the diluted samples were loaded on to a 5% to 6% polyacrylamide gel containing 8.3 mol/l urea and separated for 2 to 3 h at 80 W. Subsequently, the gel was dried and subjected to autoradiography using Kodak XAR film (Eastman Kodak, Rochester, NY, USA) at −80°C. Relative intensities of the bands from the matched peripheral blood mononuclear cells and bone marrow were examined subjectively as well as by quantitative densitometry. LOH was scored in informative cases if a significant reduction (Ͼ50%) in the signal of the allele from the bone marrow was noted in comparison to the corresponding allele in the adjacent lane from the peripheral blood of the same individual. In all samples showing LOH, PCR amplification and analysis were repeated to assure consistency of results.
Results
We have screened 32 paired bone marrow/peripheral blood samples for LOH from patients with MDS. A panel of 84 highly informative microsatellite markers was used including at least two markers on each autosomal arm. Table 1 shows the list of marker, the proportion of informative cases among the MDS samples, and the frequency of LOH at each locus. Of the 84 loci analyzed, 72 (86%) revealed LOH in one or more MDS samples. Among the chromosomes (loci) which showed LOH, the frequency varied widely, ranging from 4% (4q and 6p) to 45% (7q). Table 2 shows the clinical characteristic, site of allelic loss and the fractional allelic loss (FAL) value for the individual MDS patients.
A frequency of LOH of у20% for the informative cases was observed on chromosomal arms: 1p (36%), 1q (35%), 5q (40%), 7q (45%), 17p (23%), 18q (23%), and 20q (20%) (Figure 1 ). Among these, LOH on chromosomal arms 5q, 7q, 17p and 20q have already been reported, and our observations confirmed their findings.
6,13,14 LOH on both arms of chromosome 7 was identified in two cases (Nos 4 and 12), indicating that these samples likely have monosomy chromosome 7, as has been frequently observed in MDS. 9, 15 Representative examples of autoradiograms of LOH on chromosomal arms 1p, 1q, 18q and 20q are shown in Figure 2 .
High frequency of LOH was observed on both 1p and 1q. LOH on 1p was found in nine of 25 (36%) informative cases when analysis was done with five microsatellite markers (D1S253, D1S450, D1S436, D1S228, D1S221). The D1S436 and D1S228 markers, which map at 1p36, exhibited the highest frequency of LOH, with allelic deletion in seven of 18 (39%) and eight of 21 (38%) informative cases, respectively. Simultaneous deletion of D1S436 and D1S228 were detected in case Nos 2, 12 and 23. The other three microsatellite markers (D1S253, D1S450 and D1S221) on chromosomal arm 1p showed Ͻ10% LOH for each marker. This pattern of LOH suggests a common region of deletion encompassing chromosome 1p36. The putative tumor suppressor gene p73 has been mapped to this region, and LOH in this region has been reported in several tumors. [16] [17] [18] [19] LOH on the long arm of chromosome 1 was also frequent, occurring in eight of 23 (35%) informative cases (Table 1, Figure 1) .
Allelic loss of 23% of the informative cases was observed on chromosome arm 18q (Figure 1 ). Marker D18S58 in the DCC locus on chromosome 18q showed 5% LOH (one of 20 informative cases). In contrast, marker D18S68, which is located proximally to the DCC locus, showed 24% LOH (five of 21 informative cases), which suggests that the common region of loss was not within the DCC locus. Allelic loss of у20% of the informative cases was also identified on chromosome 20q (20%). This is consistent with the frequent deletions on chromosome 20q observed in cytogenetic studies of MDS. 20 The FAL was calculated as the ratio of chromosomal arms
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Figure 1
Frequency of allelic loss on individual chromosomal arms in MDS. Allelotyping was accomplished using polymorphic microsatellite markers. The markers are listed on Table 1 . LOH by arms is defined as the percentage of informative cases for each arm showing loss of any marker mapped to that arm.
that showed loss among all informative arms for each individual (Table 2) . 10 The FAL values, in 31 patients that showed LOH, varied from 0.03 to 0.41, with a median of 0.09 and mean of 0.13.
Discussion
To understand the role of genetic changes in the development of MDS, we performed a detailed allelotype analysis. The study revealed frequent LOH on eight chromosomal arms, including sites of previously identified deletions and novel sites that have so far not been described in MDS. This implies the involvement of tumor suppressor genes in the initiation and/or progression of MDS in these regions of LOH. Frequent LOH on chromosomal arms 5q, 7q, 17p and 20q in MDS has been reported. [6] [7] [8] The LOH at 17p is associated with a mutation of the p53 gene, which is associated with progressive MDS. 21 Although chromosomal arm 5q and to a less extent chromosomal arm 7q has been intensively studied, the target tumor suppressor genes important for MDS have not yet been identified. 7, 11, 14 The present study confirms that these chromosomes harbor tumor suppressor genes important for the development of MDS. Importantly, we detected LOH in more than 20% of the informative cases on chromosomal arms 1p, 1q, and 18q, which are regions previously not appreciated as containing genes important in MDS.
Frequent LOH on chromosome 1p has been reported in neuroblastoma, 16, 17 chronic myelocytic leukemia (CML), 22 hepatocellular carcinoma 19 and colorectal cancer. 18 However, cytogenetic deletions or LOH of chromosome 1p in MDS has rarely been reported. Using five microsatellite markers, we identified that the most frequent deleted region is 1p36. This region is the location of the putative tumor suppressor gene p73, which may be involved in some cancers including neuroblastoma, lung and breast cancers. 16, 23 Analysis of this gene in our MDS samples is ongoing.
The identification of LOH on chromosome 1q was found in 35% of our informative MDS samples. Previous studies have identified deletions at chromosome 1q21-22 in cancers of the breast, 24 colon, 10 lung, 12 and stomach. 20 Also, LOH has been reported at 1q23-32 in breast cancer. 25 Translocation between 1q and 5q, 26 trisomy 1q, 27 and either rearrangement or duplication of chromosome 1q 28 have been observed in MDS. However, deletion of chromosome 1q in MDS has rarely been reported. This study strongly suggests that one or multiple tumor suppressor genes involved in MDS are present on chromosome 1q. The identification of LOH on chromosome 18q was reported in more than 75% of colorectal cancers, 10 61% of gastric cancers, 29 and 24% of esophageal squamous cancers 30 and has been considered to be associated with a loss-of-function mutation of the DCC gene. In this study, frequent LOH on chromosome 18q (23%) was observed in MDS; however, the region of LOH did not include the DCC locus. Similar findings were also observed in a collection of ovarian cancers. 31 This implies that one or more multiple tumor suppressor genes besides DCC may be on chromosome 18q.
We did not identify microsatellite instability in our MDS cases (data not shown). Microsatellite instability, representing mutations of the short-tandem repeat nucleotide sequences, has been associated with multiple replication errors because of defective mismatch repair genes. 32, 33 Microsatellite instability has been detected in colorectal, gastric, pancreatic, and endometrial carcinomas and has been ascribed to alterations of hMSH2 and hMLH1 genes. [34] [35] [36] Four other studies have examined microsatellite instability in MDS. Ben-Yehuda et al 37 studied 16 samples and noted that microsatellite instability frequently (94%) occurred, especially in therapy-related MDS. Furthermore microsatellite instability was found in samples from patients with de novo AML. 38 In contrast, Tasaka et al 39 examined 20 cases of MDS at 16 loci and found instability in four of 240 (1.6%) informative sites. 39 Studies by two other groups also indicated that microsatellite instability is a rare event in MDS. [40] [41] [42] In general, microsatellite instability appears to be relatively infrequent in MDS.
The median and mean values of (FAL) were 0.09 and 0.13, respectively, in this study. This median value is lower than those reported for many solid tumors such as osteosarcomas (0.32), 43 colorectal carcinomas and non-small cell lung cancers (0.2), 10, 12 pancreatic adenocarcinomas (0.18), 31 and bladder cancers (0.11). 44 Thus, in comparison to many solid tumors, fewer putative tumor suppressor genes are involved in MDS. Despite the assumption that a high frequency of LOH occurs predominantly in patients with high-risk MDS, our study found that two patients with RA or RARS (Nos 4 and 12) also had a high frequency of LOH. The relationship between LOH and clinical outcome in MDS will require further study.
In summary, this LOH study suggests that multiple tumor suppressor genes are involved in MDS and that the molecular genetic profile of this tumor type is likely to be complex. More individuals need to be examined to correlate site of LOH and clinical features. The LOH in MDS probably represents a reduction to homozygosity, where one tumor suppressor allele is mutated and the second allele is lost by one of several mechanisms such as deletion or mitotic recombination. Besides the loss of tumor suppressor genes, chromosome translocations, rearrangements or duplications of chromosome have been observed in MDS. 26, 28 In addition, mismatch repair genes such as MSH2 can be altered leading to microsatellite instability as well as generalize genetic instability. 38 Furthermore, mitotic checkpoint genes can be abnormal leading to aueuploidy. 45 Using microsatellite PCR we identified chromosomal regions of loss which were not observed by conventional karyotyping indicating the importance of this PCR-based technique even in cases with normal cytogenetic findings. Additional studies should focus on detailed deletional mapping of affected chromosomal regions, which should eventually lead to isolation of candidate tumor suppressor genes that are altered in this disease.
